SynthesisBMC pregnancy and childbirth2024
Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis.
Synthesis in BMC pregnancy and childbirth, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Acute Limb Ischemia During Pregnancy: A Case Report and Narrative Review of the Literature.Journal of clinical medicine · 2026Article
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Early interventions for the prevention of preeclampsia in pregnant women at increased risk: a network meta-analysis.The Cochrane database of systematic reviews · 2026Article
- Inflammation at the Maternal-Fetal Interface: Mechanisms Linking Maternal-Fetal Immunity to Preeclampsia and Fetal Growth Restriction.International journal of molecular sciences · 2026Review
- The effectiveness of 100 mg aspirin in preventing superimposed preeclampsia in women with chronic hypertension: a real-world study.BMC pregnancy and childbirth · 2026Article
- From empirical regimens to precision prophylaxis: mechanism-based targeting of preeclampsia phenotypes.Frontiers in pharmacology · 2026Review
- Therapeutic role of low molecular weight heparin and fat-soluble vitamins in pregnancy-associated prethrombotic conditions.Frontiers in medicine · 2026Review
- Evolution of therapy for autoimmune diseases in pregnancy: a retrospective study from 2000 to 2023.Frontiers in medicine · 2026Article
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
- Kidney health outcomes of hypertensive disorders of pregnancy.Nature reviews. Nephrology · 2025Review
- Serum estradiol (E2), progesterone (P), and human chorionic gonadotropin (HCG), D-dimer (D-D) fibrinogen (FIB) levels after low molecular weight heparin sodium on preventing miscarriage in patients with adverse pregnancy and delivery.Journal of medical biochemistry · 2025Article
- Preeclampsia: Insights into pathophysiological mechanisms and preventive strategies.American journal of preventive cardiology · 2025Review
- Multifunctional applications and research advances of low-molecular-weight heparin.Frontiers in pharmacology · 2025Review
- Hypertension and associated complications in pregnant women with chronic kidney disease.World journal of nephrology · 2024Review
- Pentaerithrityl tetranitrate (PETN) for prevention of fetal growth restriction in pregnancy: A systematic review and meta-analysis.European journal of obstetrics & gynecology and reproductive biology: X · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo systematically evaluate the efficacy of low molecular weight heparin (LMWH) to prevent preeclampsia in high risk pregnant women without thrombophilia. SEARCH STRATEGY: PubMed, Embase and the Cochrane library were searched for articles published before 1st August 2022 using the combination keywords "preeclampsia", "Low Molecular Weight Heparin", "LMWH", "Heparin, Low Molecular Weight", "Dalteparin", "Nadroparin", and "Tinzaparin". SELECTION CRITERIA: Randomized controlled trials evaluating the use of LMWH in pregnant women at high risk of preeclampsia without thrombophilia. DATA COLLECTION AND ANALYSIS: Ten studies were included in the meta-analysis (1758 patients in total). Outcomes were expressed as relative risk (RR) with 95% confidence intervals (CI).
resultsLMWH reduced the incidence of PE (RR = 0.67; 95% CI = 0.50-0.90; P = 0.009) in high risk pregnant women without thrombophilia. Subgroup analysis found that the prophylactic effect of LMWH was only significant in studies using low-dose aspirin (LDA) as the primary intervention. The combination of LMWH and LDA was also effective for the prevention of preterm birth and fetal growth restriction, but had no effect on the incidence of placenta abruption.
conclusionFor women at high risk of developing preeclampsia without thrombophilia, the combination of LMWH and low-dose aspirin is effective for the prevention of preeclampsia, preterm birth and fetal growth restriction and is superior to LDA alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.